Compound Access
Psilocybin
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. [1]
Country GuideMedical AccessMedical Only (Private)
Country Access Report
Medical Access in Sudan
Sudan follows the UN drug-control framework and national narcotics legislation (Narcotic Drugs and Psychotropic Substances Act, 1994), which criminalises classical psychedelics and most psychotropic schedules; however ketamine is widely used and available as an essential anaesthetic in Sudanese hospitals. There is no public evidence of national regulatory approvals or public reimbursement pathways for specialized psychedelic medicines (e.g., esketamine, psilocybin, MDMA) — access is either routine medical use for ketamine or otherwise limited to criminalised status or research contexts.
- Access Level
- Medical Only (Private)
- Compounds Covered
- 10
- Active Trials
- 0
How To Use This Guide
Read the access level as a starting point, then check the compound notes below. The practical question is whether a patient can move through a real pathway today, or whether access still depends on a trial, exception route, private-care model, or future reimbursement decision.
Available Today
Look for approved use, named specialist settings, eligibility rules, and whether care is routine or exceptional.
Research Or Exception
Separate clinical trials, special access, compassionate use, and unlicensed-medicine routes from routine medical availability.
Payment And Delivery
Check who pays, where care can happen, and whether trained teams, product supply, and site governance are in place.
Access By Compound
These notes separate what is available today from research, exceptional-access, private-care, and payment routes. When the guide has not verified a pathway, the compound stays marked as incomplete rather than treated as unavailable.
Strictly Illegal
Compound Access
MDMA
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. [1]
Compound Access
Esketamine
There is no public record of a national regulatory approval, listing, or public reimbursement pathway for esketamine (Spravato) in Sudan; specialized intranasal esketamine products authorized in high‑income jurisdictions are not documented as approved or reimbursed in Sudanese regulatory sources. Ketamine (the racemate) is used clinically in Sudan as an essential injectable anaesthetic, but esketamine as a registered antidepressant formulation has not been identified in Sudanese public drug listings or health‑system procurement sources. [No national approval found in public sources; see national narcotics law context and WHO essential medicines listing for ketamine]. [1] [2]
Compound Access
Ketamine
Ketamine is a registered, widely used injectable anaesthetic in Sudan’s health system and is included on the WHO Model List of Essential Medicines as an injectable anaesthetic agent; Sudanese clinical literature and hospital surveys document routine ketamine availability and use for anaesthesia and emergency/surgical care in Sudan. Public reimbursement or a formal national mental‑health indication pathway for ketamine as a depression treatment (including infusion-based psychiatric protocols) is not documented—use is primarily as an anaesthetic in public and private hospitals, with procurement and availability varying by facility and region. Clinical/regulatory details: ketamine’s inclusion on the WHO essential medicines list supports its use in surgical and emergency contexts but does not create a national psychiatric reimbursement pathway in Sudan. Examples of Sudanese clinical publications reporting ketamine use in operating rooms and anesthesia practice are available. [1] [2] [3]
Compound Access
DMT
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (DMT is also listed under international psychotropic controls and Sudan implements national scheduling under its narcotics law.) [1]
Compound Access
5-MeO-DMT
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. [1]
Compound Access
Ibogaine
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. [1]
Compound Access
Ayahuasca
Because ayahuasca preparations contain DMT (a scheduled psychotropic), ayahuasca is effectively treated as a controlled substance under Sudanese narcotics legislation with no authorised medical/religious exemption in public sources; therefore no legal medical access or reimbursement pathway exists outside approved clinical research. [1] [2]
Compound Access
Mescaline
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. [1]
Compound Access
2C-X
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (2C-series compounds are typically scheduled under national psychotropic substance controls; Sudan’s narcotics framework criminalises analogous synthetic psychedelics.) [1]
Sources and Review
Last updated 2 Mar 2026. Source links come from the medical access guide.